Twenty-one patients with chronic stable angina were treated with the calcium antagonist diltiazem. Dose titration studies involving 180, 270 and 360 mg/day were conducted using a blinded objective protocol. Improvement in exercise tolerance was observed at all dose levels, but the best reduction of anginal attacks and glyceryl trinitrate consumption, enhancement of exercise capacity and improvement of objective ischemic variables were observed with the 360 mg/day dose. The mean exercise time to produce grade II angina on treadmill walking increased from 5.6 :±: 0.7 minutes on placebo to 7.9 :±: 0.8 minutes on diltiazem 180 mg/day (probability [p] < Diltiazem, a calcium antagonist drug developed in Japan and newly released in the United States and United Kingdom, has powerful coronary vasodilating properties and has been used successfully in Prinzmetal's variant angina (l,2). Some reports have suggested that it may also be effective in chronic stable angina (3) (4) (5) (6) . We conducted a controlled study to determine the efficacy of three dose levels of diltiazem as measured by a number of objective variables using exercise testing and 24 hour ambulatory electrocardiographic monitoring in patients with chronic stable angina due to obstructive coronary artery disease that had not responded to conventional therapy.
Methods
Patients. Twenty-one patients (19 men and 2 women) aged 48 to 68 years entered the study. The inclusion and exclusion criteria 0.001), 8 .0 :±: 0.8 minutes on 270 mg/day and 9.5 :±: 0.9 minutes on 360 mg/day (p < 0.001 as compared with 270 mg/day). One patient was withdrawn at the 360 mg/ day dosage because of pedal edema. The 24 hour Holter monitoring data confirmed the findings on exercise testing, and left ventricular function was not altered with any dose level. Diltiazem in doses ranging from 180 to 360 mg/day is another powerful antianginal agent in the calcium antagonist group producing excellent therapeutic benefit in chronic stable angina with no adverse effects on left ventricular function.
have been reported previously (7, 8) . The patient data and the drugs previously administered are shown in Table 1 . The initial assessment consisted of an exercise test performed at least 2 weeks after gradual and complete withdrawal of all therapy.
Trial design. The beginning of the trial consisted of a 2 week single blind placebo run-in phase. The patients then entered a double blind randomized crossover phase of diltiazem therapy. Each phase of the crossover consisted of 2 weeks of administration of the drug, 60 or 90 mg three times a day. At the end of the crossover phase, the patients entered a final phase of 2 weeks with 120 mg of diltiazem given three times a day in a single blind fashion. During the double blind phase neither the investigator nor the patient knew the dose of the drug and during the single blind phase the patients were also unaware of the nature of their medication. All tablets were packed in identical "blister" packs utilizing the double dummy technique.
Drug assessment. The effect of the placebo and diltiazem was assessed subjectively and objectively. The patients maintained a detailed diary of the frequency of their anginal attacks and the number of sublingual glyceryl trinitrate tablets consumed. They were clearly instructed as to the importance of keeping an accurate diary of anginal attacks and side effects. Sublingual nitrates were not allowed prophylactically. A = e.xerc!se time (in minutes) on previous treatment. B = exercise time on notreatment. C = exercise time on placebo: 0 = exercise time on diltiazem. 180 mg/day: E = exercise time on drltiazem, 360 mg/day: SEM = standard error of the mean administration of all medication, active or inactive, at 2 week intervals. All exercise tests were performed in the morning at least 2 hours after a light breakfast and 120 to 180 minutes after the administration of the last dose of diltiazem. The patients arrived at the exercise laboratory at least 30 minutes before the test and rested comfortably. They were instructed not to smoke or to take glyceryl trinitrate tablets on the morning of the test.
Exercise protocol. The exercise test was performed with use of a microcomputer-based system (Marquette Computer Assisted System for Exercise) linked to a Quinton treadmill (Fig. I) . The treadmill protocol is shown in Figure 2 . The speed and gradient were automatically controlled by the computer and the test was timed with a built-in digital clock to an accuracy of 0.1 minute. All tests were continued until the patient developed the following symptoms: angina (grade II), pain in the legs, severe breathlessness or fatigue. Standard safety procedures and legal requirements as recommended for adult exercise testing laboratories by the Ametican Heart Association (9) were followed. Two bipolar electrocardiographic leads were continuously monitored at rest, during exercise and for a minimum of 5 minutes after exercise. Systolic blood pressure was monitored every 3 minutes with a mercury sphygmomanometer.
Recording and measurements. The electrocardiographic leads monitored were CM 5 (manubrium sterni negative and LV 5 exploring electrode) and CC 5 (RV 6 negative and LV 5 exploring electrode); a lead showing large P waves was used to monitor arrhythmias. The test electrocardiogram was passed to the computer to form the rest template. The computer calculated ST segment depression at the J point in reference to the most horizontal part of the PR segment and expressed it in multiples of 0.1 mm (Fig.  3) . The averaged ST segment depression, heart rate and ectopic beat count were printed automatically for both leads every minute during and after exercise. During the entire test, the electrocardiogram was recorded continuously as 25 beat averages at a paper speed of I mm/s with ectopic complexes being recorded in real time. At the end of the test, the computer printed out the exercise time, maximal heart rate, maximal ST depression and ectopic complex count. A continuous trend graph of heart rate and ST depression in all three leads was also obtained. The measurement circuits of the computer were calibrated daily (Fig. 3) .
Data collection.
From the continuous printouts the following data were available:
I. Rest heart rate and ST segment levels.
2. Exercise heart rate, ST levels and ectopic complex count every minute during and after exercise. 3. Maximal heart rate, 4. Maximal ST depression (in leads CM s and CC s ).
5, Exercise time,
The following variables could then be calculated:
1. Heart rate gain = maximal heart rate minus heart rate at rest. 2, Heart rate recovery in 5 minutes = maximal heart rate minus heart rate 5 minutes after recovery. 3. Heart rate at same exercise time = heart rate after treatment at the same exercise time at which the patient experienced angina during placebo therapy, 4, I mm time = time taken to develop I mm ST depression relative to the level at rest. 9, Rate-pressure product = systolic blood pressure multiplied by heart rate and divided by 100.
10. Work done = distance walked in kilometers multiplied by the sine angle of treadmill in degrees.
Ambulatory Electrocardiographic Monitoring
Twenty-four hour ambulatory Holter electrocardiographic monitoring was performed using a frequency-modulated tape recorder (Oxford Medilog Mark 2) (Fig, 4) (10, II) with a frequency response of 0.05 to 100 Hz for the recorder and 0.1 to 100 Hz for the entire system, The recorder. The tape recorder is compact (15,2 ern x 9, I cm x 2.8 em) and contoured; it weighs only 390 g. It uses an ordinary C-120 magnetic cassette tape to record four channels of information for 24 continuous hours. The information recorded consists of two channels of electrocardiogram, clock time and flutter compensation signals, The recorder is operated by an alkaline battery and is worn by the patient with little discomfort. The electrocardiogram is acquired by a specially formulated elec- In all studies The stages last 3 minutes each At stage I, the speed IS 2 mph with no gradient. At stage II, the speed IS increased by the computer to 3 mph and the gradient to 4%. The gradient is increased by 4% every 3 minutes and the speed held constant at 3 mph. In stage VII, the speed is increased to 4.5 mph with the gradient~t 20%. Proper electrodeapplication is an absolute requirement to achieve good ST segment signals free from artifact and baseline shift. The chosen sites were over bony surfaces away from major muscle masses. The hair was shaved if necessary and the skin cleansed with isopropyl alcohol. The prepared site was outlined by a felt marker and the skin lightly abrased with a battery-operated dental burr to remove the epidermis. The electrodes were then applied and the cables connected. The electrodes and cable junctions were attached to the skin with adhesive plaster and the recorder fitted into a pouch worn on the front of the chest. The recorder and cables were snugly fixed to the chest with an elastic vest to eliminate movement.
Tape analysis (Fig. 5 ). Tape analysis is performed in three stages:
1. Visual inspection. The tape signal was recalled using an Oxford PB4 replay unit and displayed on a Reynolds Medical Pathfinder (Reynolds Medical). The quality of the tape recording and any gross abnormalities were appraised by the operator during this phase. using the trend system to identify the ST segment. The Reynolds Medical trend system generates two bright spots, one of which was placed manually on the PR isoelectric line and the other at the J point. The electrocardiogram was then displayed continuously and the system measured the voltage difference between these two points averaged for 10 beats with automatic rejection of artifact and ectopic beats. The system performed simultaneous RR interval analysis and the ST segment and heart rate changes were registered graphically as an analog trend chart using two channels of a linear recorder; the analyzer related the changes to the standard calibration signals. This presentation permitted rapid visual assessment of patterns of ST depression or elevation that could be related to time events from a diary card and was amenable to semiquantitative analysis.
3. Quantitative analysis. The digital system was designed to work with the Reynolds Medical ST trend system. An interfacing module was built to enable the calibrated heart rate and ST segment change from the trend system to be transferred into a commercially available minicomputer (MINC PDP 11/23) with twin 8 inch (20.3 ern) floppy disc drives. The computer was programmed to give an on-line data analysis option and an off-line data retrieval and analysis option.
Computer program. The initial program "menu" consisted of patient identification, recorder identification, the electrocardiographic leads recorded, time of starting the recording, times of symptoms and the date of the recording. The zero reference point was transferred to the computer together with the I mV square wave calibration pulses recorded on each tape. The computer was programmed to reject noisy or distorted calibration signals and produce an average of 15 pulses. If a satisfactory calibration signal was not obtained, a standard internal calibration could be utilized. The tape deck was then started and the signals passed continuously into the computer. The computer program also contained noise rejection and artifact-sensing circuitry. Once the tape was run through, the data were transferred to a floppy diskette for future analysis and retrieval. The entire procedure of digitizing took about I hour per tape for two electrocardiographic channels.
The data stored on each floppy diskette were mean heart rate, maximal heart rate, minimal heart rate, mean ST depression, maxGlock time • Maximal 5T l
imal ST depression and minimal ST depression for every minute. Software programming enabled the operator to recall any period either as minute values or as averaged values. The operator could preset variable normal limits, and the total time duration and the mean ST change were also available to allow calculation of the area of ST depression in a given time. In addition, the off limit ST values or heart rate values could be deleted or included and identified by distinct markers. With this program, digital anaylsis could be performed in less than 1 minute per sequence after the data had been stored in the diskettes. A graphic plotting program enabled a trend to be generated from digital values within 30 seconds.
Left Ventricular Function
Left ventricular function was measured noninvasively by systolic time intervals measured in the supine posture. The first derivative of the electrical impedance cardiogram (dZ/dt) (12) was used as the central arterial pulse waveform. The impedance cardiogram and the electrocardiogram were simultaneously fed into a minicomputer that calculated the systolic time intervals (Fig. 6 ) (13). We used 100 beat averaging during quiet supine rest with additional averaging of the first 20 beats with the breath held in expiration. All studies were performed in the morning after 20 minutes of supine rest. The data obtained included heart rate, preejection period (PEP), left ventricular ejection time (LVET), PEPI LVET ratio, RZ interval and (dZ/dt)/RZ ratio (14) (15) (16) (17) (18) .
Clinical assessment and plasma drug levels. During each visit, the patients were questioned in detail from a standard questionnaire to elicit side effects and examined for pedal edema, raised jugular venous pressure and basal crepitations. Routine biochemical investigations were performed at each visit. Plasma diltiazem levels were estimated at each period by gas liquid chromatography (19) and blood was collected 120 to 150 minutes after the last dose of the drug. The serum diltiazem levels and tablet counting were used to test compliance. The compliance in taking the drugs appeared to be exceptionally good because of the low side effects profile of the drug. The side effects were carefully monitored by a combination of diaries kept by the patient and inquiries from the standard questionnaire at the time of each clinic visit. Statistical analysis was performed using Student's paired t test. Informed consent was obtained from each patient and the protocol was approved by the Hospital Ethical Committee.
Results
The previous drug treatment consisted of beta-adrenergic receptor blocking drugs in 10 patients, calcium ion antagonist drugs either alone or in combination in 10 patients and molsidornine in 1 patient (Table 1 ). All patients entered the diltiazem trial after gradual and complete withdrawal of all treatment except sublingual glyceryl trinitrate. Twenty of the 21 patients completed all four phases of the study and 1 was withdrawn during the 120 mg three times a day phase because of pedal edema.
Exercise tolerance (Fig. 7) . All 21 patients developed classic angina during treadmill exercise at the end of the placebo phase. Their exercise tolerance ranged from 1.7 to 13.2 minutes on the standard exercise protocol. The mean exercise time (± standard error of the mean) to produce angina during placebo administration was 5.5 ± 0.7 minutes. Five patients developed angina within 3 minutes of walking at 2 miles per hour with no gradient (stage 1), eight within 6 minutes (stage ll), four in stage Ill, three in stage IV and one in stage V.
Treatment with diltiazem, 60 mg three times a day, rendered 2 of 21 patients angina-free on treadmill exercise and increased exercise tolerance to a mean of 7.9 ± 0.8 minutes exercise time of 8.0 ± 0.8 minutes was not significantly different from that with the 60 mg three times a day dose. The dose of 120 mg three times a day produced a marked improvement in exercise tolerance as compared with placebo and other drug dose levels. Eight patients became angina-free during exercise and the mean exercise time improved to 9.8 ± 0.8 minutes (p < 0.001 versus placebo and lower doses).
The incidence of anginal attacks was 26 ± 8 episodes per week on placebo. This decreased to 23 ± 10 episodes per week on diltiazem, 60 mg three times a day, and to 15 ± 5 episodes on 90 mg three times a day. A further reduction (p < 0.01) to 8 ± 4 episodes occurred on the 120 mg three times a day schedule. A mean of 33 ± 10 glyceryl trinitrate tablets was consumed during the placebo period, decreasing to 21.4 ± 10 on 60 mg three times a day, 12 ± 3 on 90 mg three times a day and 9 ± 4 on 120 mg three times a day, respectively. The values obtained with diltiazem, 120 mg three times a day, were significantly better than those with placebo (p < 0.01).
ST segment changes ( Table 2 ). The mean exercise time required to develop I mm ST depression from the level at rest was 3.4 ± 0.4 minutes (range 1.0 to 7.0) on placebo. With the 60 mg three times a day diltiazem dose, this improved to 4.8 ± 0.5 minutes (p < 0.001). There was no further change at the 90 mg three times a day dose (5.0 ± 0.6 minutes) but there was a significant increase at the 120 mg three times a day dose. Similar changes were seen in the 2 mm ST depression time. The peak ST segment change on termination of exercise increased from -1.9 ± 0.1 mm on placebo to -2.2 ± 0.2 mm on the 120 mg three times a day dose (p = NS). There was a progressive decrease in the maximal ST depression/exercise time with each increase in dose and, with the exception of the difference between the values at the 90 and 120 mg three times a day dose levels, these differences were statistically significant. The ST segment recovery remained unaltered at all dose levels despite a marked improvement in exercise tolerance .
Heart rate ( Table 2 ). The mean heart rate at rest was 75 ± 3 beats/min with placebo. This decreased to 65 ± 2 beats/min on 60 and 90 mg three times a day and to 64 ± 2 beats/min on 120 mg three times a day. The maximal heart rate was 123 ± 3 beats/min on placebo and remained unchanged with diltiazem treatment. The heart rate gain showed a slight but insignificant increase. The heart rate gain per minute of exercise was 8.8 beats/min on placebo. This decreased to 6.8 beats/min of exercise on the 60 mg three times a day dose and to 5.9 beats/min of exercise on the 90 mg three times a day dose. No further change was observed with the 120 mg dose. There was also no change in the heart rate recovery in the postexercise period, and the peak rate-pressure product was not altered by treatment. I mm time = time taken for developing I mm ST depression relative to resnng level. 2 mm time = time taken for developing 2 mm ST depression relative to resung level; Ex. time = exercise time in minutes; HR = heart rate/rmnute, MST = maximal ST depression (mm). NS = not sigrnficant: p = probabihty valve: pI = P value between placebo and 180 mg/dayof dilnazern; p2 = P value between placeboand 360 rug/day. p3 = P value between 180and 270 rng/day: p4 = P value between 180 and 360 mg/day All values are mean ± standard error of mean All ST segment values are In rnm, all heart rate values are In beats per minute. all timed vanables are In minutes and rate-pressure product is the product of systolic blood pressure and heart rate divided by 100 uruts
The exercise data of a patient during placebo and diltiazem therapy are shown in Figures 8 and 9 .
Twenty-four hour ambulatory monitoring. No patient showed prolongation of the PR interval or higher degrees of heart block. All the dose levels of diltiazem produced a moderate reduction of ambulatory heart rate that was significantly less than that with placebo (Fig. 9) . There was no significant difference among the various dose levels. The mean number of minutes in which the ST segment was depressed more than I mm in lead eMs was 74 ± 23 during placebo adminitration. This was significantly reduced to 22 ± 5 minutes during treatment with 120 mg three times a day of diltiazem (p < 0.05). The total area of ST segment depression in 24 hours was 127 ± 40 units on placebo and this was reduced to 63 ± 20 units on diltiazem (p < 0.05).
The maximal depth of ST segment depression was 2.2 mm on placebo and this was not significantly altered by diltiazem. The number of minutes in 24 hours during which the mean heart rate exceeded 100 beatslmin was 95 ± 30 on placebo but only 33 ± 15 minutes on diltiazem (p < 0.05).
Left ventricular function. No significant changes in any of the measured variables were observed with any of the dose levels of diltiazem.
Plasma drug levels. The mean plasma levels during 60 mg three times a day di1tiazem therapy ranged from 58 to 236 nglml (mean 118 ± 15). This increased to 172 ± 26 ng/ml (range 74 to 333) with the 90 mg three times a day dose and 256 ± 24 nglml (range 102 to 434) on the 120 mg three times a day dose.
Side effects. One patient was withdrawn from the study because of the occurrence of ankle edema during the treatment with 120 mg three times a day. This patient had tolerated the lower doses without any side effects. One patient complained of swelling and stiffness of the fingers and three patients complained of shoulder and elbow pain on the 120 mg three times a day dose. These complaints were not severe enough to require treatment or withdrawal of the drug. Generally the drug was very well tolerated with minimal side effects.
Biochemical profile. Three patients showed an increase in serum creatine kinase values above the normal range. One patient had a placebo level of 266 IUlliter and this 
Discussion
There have been important advances in therapy aimed at preventing anginal attacks over the last 20 years. Betaadrenergic blocking agents have become widely used and produce symptomatic and objective improvement in more than 50% of patients with chronic stable angina (20) (21) (22) . Calcium channel blocking agents have been widely used for vasospastic angina and have been found useful in chronic stable angina (23) . We carried out controlled trials with verapamil and reported excellent symptomatic and objective improvement with this calcium antagonist (7, 8) . However, our experience has shown that there is a group of patients who either cannot tolerate these drugs or do not obtain adequate relief despite high dosage. These patients would normally be considered for coronary artery bypass surgery for relief of symptoms. The availability of another effective drug could offer a useful alternative therapy for these patients to either delay or obviate the need for surgery.
Antianginal effects of diltiazem. Diltiazem greatly improved the exercise tolerance of the patients and there was a dose-dependent increase in the number of patients rendered angina-free (eight with the highest dose level). There was a dose-dependent increase in the mean exercise time and improvement in other objective variables. The smallest dose was moderately effective and the best effect was seen with 120 mg three times a day. Unlike findings with beta-adrenergic receptor blocking agents, increasing dose was not associated with increasing bradycardia at rest, and the initial heart rate reduction of 11 beats/min was maintained. Side effects were minimal. It is possible that the lower dose may be adequate in patients with milder angina and higher doses may be tried in patients with more severe pain; other workers (3-6) have reported that diltiazem is effective at doses lower than those found effective in our patients, who had relatively severe and resistant angina. Other effects of diltiazem: comparison with verapamil. The pharmacologic action of diltiazem appears similar to that of verapamil (24) . The preparation used in this trial was a controlled-release formulation with a half-life of about 5 hours. The heart rate at rest was moderately reduced but the maximal heart rate and peak rate-pressure product were unchanged. Similarly, the ST segment depression at maximal exercise was unaltered. However, there was a marked attenuation of heart rate gain during exercise. We noted similar effects with verapamil (7, 8) . The main difference from diltiazem was the absence of constipation as a side 1 AM COLL CARDIOL 1983:1(4).1144-53 BALA SUBRAMANIAN ET AL Ambulatory hourly mean heart rate Placebo, diltiazem, 60,90 and 120 mg In = 21) 90 ++++++ Figure 9 . Mean hourly heart rates during 24 hour ambulatory electrocardiography monitoring in 21 patients during treatment with placebo and with diltiazern, 60, 90 and 120 mg three times a day.
• effect and improvement in exercise tolerance in patients already resistant to verapamil. Clinically, we have seen patients resistant to diltiazem responding to verapamil, and the availability of both drugs should expand the physician's choice for treating chronic stable angina. The only biochemical abnormality observed was an increase in serum creatine kinase levels in three patients who had elevated levels initially. The serum creatine kinase level should be monitored in patients needing the highest dose level if they show an already elevated level before treatment. The protocol used in this study has been reported previously (7, 8) . It was designed to eliminate observer bias and subjective variations and yield a number of computerized objective variables to give a clear pharmacologic action profile of the drug. We have investigated several antianginal drugs using an identical protocol and the efficacy of diltiazem compares favorably with that of verapamil (22) . The reproducibility of exercise time in this group was satisfactory. The untreated mean exercise time was 5.3 ± 0.6 minutes and the placebo value was 5.5 ± 0.7 minutes (p = not significant).
The ambulatory monitoring data confirmed the findings on exercise testing. The maximal depth of ST segment depression was not altered but the duration and area of ST segment depression during 24 hours were reduced. The heart rate was reduced at all dose levels and there was no significant difference among the various dose levels.
Left ventricular function as estimated by 100 beat-averaged systolic time intervals showed no change with diltiazem therapy. This was our experience with other calcium antagonists.
In conclusion, diltiazem is a calcium channel blocker with a powerful antianginal action and minimal side effects. It is effective in patients resistant to other antianginal agents and merits a place among the first line antianginal drugs.
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